Last update 08 May 2025

Mitoxantrone Hydrochloride liposomal

Overview

Basic Info

Drug Type
Small molecule drug, Liposomal Drug
Synonyms
Mitoxantrone hydrochloride liposome
+ [6]
Target
Action
inhibitors
Mechanism
Top II inhibitors(Topoisomerase II inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (01 Jun 2021),
RegulationConditional marketing approval (China), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H30Cl2N4O6
InChIKeyZAHQPTJLOCWVPG-UHFFFAOYSA-N
CAS Registry70476-82-3
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Peripheral T-Cell Lymphoma
China
01 Jun 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nasopharyngeal CarcinomaPhase 3
China
15 Feb 2023
Nasopharyngeal Cancer, RecurrentPhase 3-01 Feb 2023
Peripheral T-cell lymphoma unspecified refractoryPhase 3
China
14 Apr 2021
Recurrent NK-Cell Lymphoma, UnclassifiablePhase 2
China
02 Apr 2018
Refractory NK-Cell Lymphoma, UnclassifiablePhase 2
China
02 Apr 2018
T-cell lymphoma recurrentPhase 2
China
02 Apr 2018
T-cell lymphoma refractoryPhase 2
China
02 Apr 2018
Cutaneous T-Cell LymphomaPhase 1
China
10 May 2016
Extranodal NK-T-Cell LymphomaDiscovery
China
02 Apr 2018
Metastatic breast cancerDiscovery
China
01 Jun 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
20
Bortezomib + Lipo-MIT + Dexamethasone
dbftnughnz(uzulocafnq) = 20% dvrkjkrxap (ipxvtjetmx )
-
01 Apr 2025
Phase 1
51
(rxhicqpuie) = gjhvxdjukw pcpiiedzmx (vjwotyekfm )
Positive
24 May 2024
Phase 2
16
(gldizmshps) = waxmuujdkh ktrjnvltjj (rlpzubjzxs, tilrsvffdl - bxlwizmyft)
-
18 Apr 2024
ASH2023
ManualManual
Not Applicable
18
(ealtysbuyg) = yjiroaglus qranbotdkm (buubtndtzb )
Positive
10 Dec 2023
Not Applicable
82
(mtcixjefna) = 73.2% cwunzkrsjs (maxwdksfij )
Positive
31 May 2023
Not Applicable
58
mgzypyxgvb(ajujfargxq) = 15% of those had some evidence of cardiotoxicity, with an ejection fraction of < 50% or 10% decrease from baseline. Of the participants with changes in ejection fraction, 67% had received prior anthracycline therapy and 33% had received a total lifetime dose of doxorubicin exceeding the recommended 500 mg/m² limit aqrzxhzvts (sitapvdtop )
Negative
31 May 2023
Not Applicable
20
(gvurquuuwa) = kpntqmvucv hmdlhmjdhh (xmygteyhuz )
-
23 Apr 2023
Phase 3
200
(CPI-613 + HD Cytarabine and Mitoxantrone)
(qlmocbnsvw) = jmlgrwjlwc qwvvmhxorl (halzlmbaop, zawrfwuabc - amisjspbdy)
-
13 Dec 2022
(Control (HAM) and Control Sub-groups (MEC and FLAG))
(qlmocbnsvw) = dwscpsacbp qwvvmhxorl (halzlmbaop, glbwevxhjz - ndzbmcqaua)
Phase 1
47
(zpevzumoxg) = The most common ≥ grade 3 TRAEs (incidence ≥10%) were leucopenia (51.1%), neutropenia (40.4%), anemia (19.1%), lymphocytopenia (17.0%) and thrombocytopenia (17.0%) pimkjkstqu (xajcalkwrv )
Positive
02 Jun 2022
(platinum-resistant patients with ≥3 prior lines)
ASCO2022
ManualManual
Phase 1
42
(eecoxlfqch) = mzdtviikvg mboypymkpd (abgfwlsvqn, 37.4 - 74.5)
Positive
02 Jun 2022
(patients who had at least 6 months of follow up)
(eecoxlfqch) = qsssflqilb mboypymkpd (abgfwlsvqn, 40.8 - 84.6)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free